Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

Phase 2

Terminated

• Conditions: Recurrent Acute Lymphoblastic Leukemia; CD22 Positive; Refractory Acute Lymphoblastic Leukemia
• Interventions: Biological: Inotuzumab Ozogamicin

• Registration Number: NCT03094611
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with CD22 positive acute lymphoblastic leukemia that has come back or does not respond to treatment. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.

Detailed Description

PRIMARY OBJECTIVES:

I. To evaluate the objective response rate of low dose of inotuzumab ozogamicin as measured by the hematologic remission rate (complete remission \[CR\] + CR with incomplete platelet recovery \[CRp\] + CR with incomplete bone marrow recovery \[CRi\]) in patients in first, second or later salvage setting.

SECONDARY OBJECTIVES:

I. To evaluate the overall safety profile and the efficacy; the efficacy is measured by the hematologic response rate (CR + CRi + PR), durations of response (DoR) and remission (DoR1), progression free survival (PFS), and overall survival (OS).

OUTLINE:

Patients receive inotuzumab ozogamicin intravenously (IV) over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.

Study Timeline

• Study First Submitted: 2017-03-20
• Study First Submitted QC: 2017-03-28
• Study First Posted: 2017-03-29
• Study Start: 2017-11-30
• Primary Completion: 2020-03-11
• Study Completion: 2020-03-11
• Results First Submitted: 2021-02-01
• Status Verified: 2021-03
• Results First Submitted QC: 2021-03-17
• Last Update Submitted: 2021-03-17
• Results First Posted: 2021-04-12
• Last Update Posted: 2021-04-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

• Patients at least 12 years of age

• Patients with a diagnosis of CD22-positive acute lymphoblastic leukemia (ALL) based on local immunophenotyping and histopathology who have:

  • Refractory disease, defined as disease progression or no response while receiving their most recent prior anti-cancer therapy,
  • Relapsed disease, defined as response to their most recent prior anti-cancer therapy with subsequent relapse

• Performance status of 0 to 3

• Serum creatinine =< 2 x upper limit of normal (ULN) or estimated creatinine clearance >= 15 mL/min as calculated using the method standard for the institution

• Total serum bilirubin =< 1.5 x ULN unless the patient has documented Gilbert syndrome. If organ function abnormalities are considered due to tumor, total serum bilirubin must be =< 2 x ULN

• Aspartate and alanine aminotransferase (AST or ALT) =< 2.5 x ULN

• No active or co-existing malignancy requiring chemotherapy or radiation within 6 months

• Female subjects of childbearing potential should be willing to use effective methods birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. Effective methods of birth control include birth control pills or injections, intrauterine devices (IUDs), or double-barrier methods (for example, a condom in combination with spermicide)

• Male subjects should agree to use an effective method of contraception starting with the first dose of study therapy through the duration of treatment

Exclusion Criteria

• Pregnant or nursing women
• Known to be human immunodeficiency virus (HIV)+
• Philadelphia chromosome (Ph)+ ALL
• Active and uncontrolled disease/infection as judged by the treating physician
• Unable or unwilling to sign the consent form
• Prior allogeneic stem cell transplantation (ASCT) or other anti-CD22 immunotherapy within =< 4 months before first dose of study treatment
• Active central nervous system (CNS) or extramedullary disease unless approved by the principal investigator (PI)
• Monoclonal antibodies therapy within 2 weeks before study entry
• Radiotherapy and cancer chemotherapy (except for intrathecal chemotherapy, hydroxyurea, and cytarabine. Cytarabine and hydroxyurea are allowed to be used emergently in case of leukocytosis) or any investigational drug within 2 weeks before study entry
• Evidence or history of veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (inotuzumab ozogamicin)	Inotuzumab Ozogamicin	Patients receive inotuzumab ozogamicin IV over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.

Primary Outcome Measures

Name	Time	Method
Number of Participants to Achieve Complete Remission (CR)	Up to 2 years	Complete Remission (CR) is the normalization of the peripheral blood and bone marrow with \</= 5% blasts with a granulocyte count of 1X10\^9/L or above and a platelet count of \>/= 100X10\^9/L and absence of extramedullary disease.

Secondary Outcome Measures

Name	Time	Method
Overall Survival	Up to 3 years	Time from date of treatment start until date of death due to any cause or last Follow-up.
Duration of Response	Up to 3 years	The date of Complete Response to the date of loss of response or last follow-up.
Participants With a Grade 3 or 4 Non-hematologic Adverse Event (AE)	Up to 2 years	For the purpose of toxicity monitoring, toxicities are defined as any treatment -related grade 3 or 4 non-hematologic AEs occurred any time during the trial.NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 utilized for adverse event reporting.
Progression Free Survival	Up to 3 years	Time from date of treatment start until the date of first objective documentation of disease-relapse.

Trial Locations

Locations (1)

M D Anderson Cancer Center; 🇺🇸 Houston, Texas, United States